drugset
drugset / Trial / NCT04803201

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

NCT04803201 ↗

Phase 2 Suspended 170 enrolled Alliance for Clinical Trials in Oncology National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.

Timeline

Start
2021-10-08
Primary completion
2027-05-19
Completion
2027-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Oral
Subject Duvelisib Small molecule — Oral
Background Cyclophosphamide Other / unclassified — Intravenous
Background Doxorubicin Other / unclassified — Intravenous
Background Etoposide Small molecule — Intravenous
Background Prednisone Other / unclassified — Oral
Background Vincristine Small molecule — Intravenous

Indications

Nodal T-follicular helper cell lymphoma, follicular type angioimmunoblastic T-cell lymphoma enteropathy-associated T-cell lymphoma monomorphic epitheliotropic intestinal T-cell lymphoma peripheral T-cell lymphoma, not otherwise specified